Search

Your search keyword '"Avet Loiseau, Herve"' showing total 1,053 results

Search Constraints

Start Over You searched for: Author "Avet Loiseau, Herve" Remove constraint Author: "Avet Loiseau, Herve"
1,053 results on '"Avet Loiseau, Herve"'

Search Results

3. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

6. TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation

7. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

9. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

12. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

13. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

14. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

15. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

16. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

18. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

20. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

21. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

23. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

25. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

27. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

30. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

31. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

34. Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival

37. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

39. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

44. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

45. RAS/RAF landscape in monoclonal plasma cell conditions

46. P-369 Single cell multi-omic correlation of single nucleotide variants, copy number variation and surface epitopes for clonal profiling of myeloma

47. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study

48. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

49. Prognostic role of circulating exosomal miRNAs in multiple myeloma

50. Timing the initiation of multiple myeloma

Catalog

Books, media, physical & digital resources